Skip to content
Film Television Auditions – Lifestyle
Author:
Inhibrx Biosciences, Inc.
Inhibrx Reports Third Quarter 2026 Financial Results
November 13, 2026
Inhibrx Announces Participation in Upcoming Scientific Conferences
October 13, 2026
INBRX-106 Trial Shows Near Double Response Rate in HNSCC
September 8, 2026
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
September 4, 2026
Inhibrx Reports Second Quarter 2026 Financial Results
August 13, 2026
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million
July 16, 2026
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
June 15, 2026